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Accurate risk prediction of cardiovascular disease (CVD) is of importance not only for the individual at risk, but also for the treating physician as well as the health care system in general, to make estimates of unmet needs for preventive efforts in a defined population. Traditionally, we have used clinical experience and personal knowledge of the individual if he or she is already a patient within the health care system coming for a consultation visit. Another aspect is to meet people from the population participating in health screening projects or coming in for a simplified health survey, sometimes paid for by themselves or their employer. Over the years, different risk algorithms have been developed and tested in European populations, from the modified Framingham Risk Score (FRS) to the updated European SCORE system, and including other systems in the UK. Some of these are discussed in recent guidelines in Europe 1 and the US. Traditionally, these algorithms have been based on variables such us age, sex, blood pressure, smoking and lipid levels, but other risk markers have also been used when available, such as left ventricular hypertrophy in FRS, or lipid fractions other than total cholesterol. Background information on diabetes and family history should often be taken into consideration but are not quantified. More recently, in the era of genomics and the search for biomarkers reflecting risk, attempts have been made to expand the traditional risk prediction algorithms by use of such biomarkers. 3, 4 This has been based on prospective analyses in populations invited for health screenings and followed over a number of years for incident cardiovascular events such as coronary heart disease manifestations or stroke. One shortcoming is that the older cohorts from some decades ago did not include the modern biomarkers, and that more modern and data-rich cohorts with excellent biobank resources are characterized by a more restricted follow-up time. This can be compensated for by including a large number of screened participants, as in the UK Biobank cohort, 5 where a high number of incident CVD events will accrue more rapidly. In the modern era of proteomics, a very wide range of potential risk markers can be analysed, 6 and in some studies this is currently the case using protein panels.
The most widely used contemporary cardiovascular biomarkers are the natriuretic peptides in the diagnosis and prognosis of heart failure, and cardiac troponins in the diagnosis of acute myocardial infarction. Numerous other biomarkers related to diagnosis, prognosis and risk prediction have been identified, but few have been adopted in everyday clinical practice. This was discussed in a recent review 4 addressing some selected main groups of cardiovascular pathology: myocardial injury (cardiac troponins, heart-type fatty-acid-binding protein, cardiac myosin binding protein-C); myocardial stress (A-type and B-type natriuretic peptides, midregional pro-adrenomedullin, copeptin); chronic inflammation (C-reactive protein, interleukin 6, growth differentiation factor 15, soluble suppressor of tumorigenicity 2, galectin-3); platelet activation (soluble CD40 ligand, P-selectin); plaque instability (lipoprotein-associated phospholipase A2, matrix metalloproteinase-9); systemic stress (catecholamines, granin proteins); and calcium homeostasis (secretoneurin). 4 This shows that there is no lack of potential biomarker candidates for screening of cardiac or cardiovascular risk.
In this issue of the journal, a research team based in Denmark has analysed three biomarkers in the Copenhagen part of the MONItoring of trends and determinants in CArdiovascular disease (MONICA) study. 7 The authors used data on 1951 subjects with baseline measurements in 1993-1994. During a median follow-up of 18.5 years, in all 177 subjects (9.1%) died from a cardiovascular cause. The aim was to examine whether high-sensitivity C-reactive protein (hs-CRP), N-terminal pro-brain natriuretic peptide (NT-proBNP) and soluble urokinase plasminogen activator receptor (suPAR) carried incremental prognostic value in predicting cardiovascular morbidity and mortality beyond traditional risk factors in these apparently healthy individuals. Predictive capabilities of each of the three biomarkers were tested using Cox proportional-hazards regression, Harrell's concordance index (C-index) and net reclassification improvement (NRI). The results indicated increased independent risk prediction for hs-CRP (adjusted standardized hazard ratio (HR): 1.37, 95% confidence interval (CI): 1.17-1.60), NT-proBNP (HR: 1.90, 95% CI: 1.58-2.29) and suPAR (HR: 1.35, 95% CI: 1.17-1.57) after adjustment for age, sex, smoking status, systolic blood pressure and total cholesterol (p < 0.001 for all). Furthermore, all three biomarkers were significantly associated with significant NRI. However, only NT-proBNP significantly raised the C-index in predicting cardiovascular mortality when added to the risk factors (C-index 0.860 versus 0.847; p ¼ 0.02). The authors concluded that hs-CRP, suPAR and particularly NT-proBNP predicted cardiovascular death and may enhance prognostication beyond traditional risk factors in apparently healthy individuals.
The take-home message from these analyses was that perhaps NT-proBNP is the most important risk marker and could be incorporated in future risk algorithms, even if the other risk markers were also able to predict somewhat differing endpoints. 7 However, it is notable that the analyses did not adjust for simple things like family history of CVD with early onset. This is an integrated part of the overall assessment of risk, but sometimes hard to quantify and also prone to bias. The argument could be raised that a simplified risk estimation based on questions during everyday consultation (or included in a screening questionnaire) could be equally effective for risk prediction as compared to a more extensive risk algorithm that includes several biomarkers based on laboratory analyses. This was shown in a population-based screening study in primary health care in Sweden when a simplified clinical risk model (without any biomarkers) was compared to an extensive biomarker model. 8 In summary, on the one hand we need expanded knowledge on the web of causation behind cardiovascular risk development, when the new omics and biomarkers will be helpful, but on the other hand we also need simplified risk calculations (algorithms) for everyday practice, or applicable in population-based screening projects. When simplified models are used we may risk to be less precise, and may even risk missing some individuals at moderately elevated cardiovascular risk, but will still have the opportunity to reach out for broader strata of the population aiming for simplified interventions based on lifestyle and eventually a polypill, as was recently evidenced in the successful PolyIran intervention study. 9 Among the new biomarkers available, only three were selected in the present publication 7 when NT-proBNP turned out to be the most efficient predictor of cardiovascular mortality. The findings should ideally be replicated in other corresponding population-based cohorts, but also analysed according to cost-effectiveness. This is why the balanced answer to the question ''Do we really need more biomarkers for cardiovascular risk prediction?'' could be ''Yes'' if we want to increase our knowledge of added risk based on new mechanistic understanding, but probably ''No'' if we want to implement such biomarker strategies in a larger screening setting when simpler methods and approaches could prove to be more cost-effective.
The advocates of the Polypill strategy 10 raise an argument to forget about the fine-tuning of cardiovascular risk assessment and just opt for simple interventions in all consenting people aged 60 years or above, especially those with a positive family history of early onset CVD, a background of heavy smoking over many years or elevated blood pressure -treated or not (as many patients are not controlled). Is this a more realistic future perspective for cardiovascular risk assessment on a global scale and within limited resources? Yes, most likely.
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